Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma.

ABSTRACT: Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood. We analyzed 528 MM patients who presented to our institution between 2014 and 2021 and who had undergone molecular testing. We defined EMD as organ plasmacytoma distinct from bones and evaluated patients for the development of EMD with the goal of defining their molecular characteristics. Here, we show that RAS/BRAF mutations are likely essential for the development of EMD. Our results also indicate that the underlying reason for the negative outcomes in patients with poor prognostic factors such as duplication 1q and deletion 17p is largely due

SUBMITTER: Nakamoto-Matsubara R 

PROVIDER: S-EPMC11666541 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature